<DOC>
	<DOCNO>NCT01555606</DOCNO>
	<brief_summary>The purpose study develop database contain patient-reported information may use understand increase awareness impact moderate-to-severe plaque psoriasis daily life life general patient 's perspective . The database include self-reported patient narrative topic experience moderate-to-severe plaque psoriasis include information treatment receive , well de-identified clinical photograph take course disease .</brief_summary>
	<brief_title>An Observational Study Evaluate Patient-Reported Experiences Living With Moderate-to-Severe Plaque Psoriasis</brief_title>
	<detailed_description>This study plan primary objective develop database contain patient-reported information may use understand increase awareness impact moderate-to-severe plaque psoriasis daily life life general patient 's perspective . This multicenter observational ( drug give patient ) patient narrative study . The duration study 16 week include adult patient moderate-to-severe plaque psoriasis candidate phototherapy systemic therapy . The study investigator dermatologists treat patient moderate-to-severe plaque psoriasis . The study include screen visit 2 week Week 0 ( baseline ) . Patients evaluate screen current peak historical physician 's global assessment ( PGA ) response ( range 0-5 ) . Patients provide narrative Week 0 ( baseline ) visit may add additional information interval visit end study Week 16 . Photography perform Week 0 end study Week 16 . Additional photograph take change disease status ( e.g. , disease improvement worsening , change treatment ) occur prior end study . Between Week 0 Week 16 , patient may return study site 1 interval visit first clinically significant change disease status , applicable . The Week 16 final assessment may conduct telephone follow-up patient interval visit Week 0 Week 16 . If patient return study site interval visit , patient return study site visit Week 16 . All assessment specify interval visit perform Week 16 . All patient follow data collect : PGA score , area body involve , body surface area percent ( BSA % , calculate percent body surface area affect psoriasis ) , Psoriasis Area Severity Index ( PASI ) de-identified photograph , adverse event , patient narrative . The information collect de-identified . Study material ( e.g. , demographic disease characteristic form , narrative , photograph ) cod use unique patient identification ( ID ) number . Only de-identified information available Sponsor relate study personnel .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Adult male female patient diagnosis plaque psoriasis least 6 month prior screen Patients candidate currently receive follow : a. conventional systemic agent ( eg , MTX , acitretin , cyclosporine , fumarates , systemic psoralens plus ultraviolet A light [ PUVA ] ) , b. topical therapy and/or phototherapy ( eligible , currently receive oral systemic biologic therapy ) , c. biologic therapy moderate severe plaque psoriasis Have peak historical current physician 's global assessment ( PGA ) great equal 3 ( range 05 ) Patients must ability read speak English Patients must reside US . Patients guttate , erythrodermic , pustular psoriasis ( various type psoriasis ) Patients serious concomitant illness could require use systemic corticosteroid otherwise interfere patient 's participation trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Patient-reported outcome</keyword>
	<keyword>Quality Life</keyword>
</DOC>